Edwards Lifesciences price target raised to $96 from $86 at Canaccord Canaccord raised its price target on Edwards Lifesciences (EW) to $96 based on the worldwide patent litigation settlement with Medtronic (MDT). The firm believes the agreement removes an expensive distraction for the business and retains the goodwill of physicians. Shares are Buy rated.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.